SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Sun Yat-sen — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientSun Yat-sen
Date of birth1866-11-12
IdentifiersMRN HR-ET016-SYN-TD; SSN (made up) 000-16-4183
Document date1924-05-18
AuthorWen-Li Huang, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Results of the liver mass work-up and medical oncology consultation. [S]

History of Present Illness

Mr. Sun returns two weeks after his first visit and is seen the same day by Dr. Choi of medical oncology. He had the multiphase CT eleven days ago, the MRI with MRCP a week ago and the ultrasound-guided core biopsy five days ago; the biopsy site was sore for a day. He asked to see the images and went through them with Dr. Huang and Dr. Choi. The ache under his right ribs is 2 of 10 on acetaminophen once or twice a day, and he is eating five small meals a day. He has had no jaundice, itching, dark urine, fever or vomiting. He is still working full days and asked for a plain account of the findings and the choices. [S]

ElementDetail
Tests doneMultiphase CT, MRI with MRCP, core biopsy of the liver mass
Pain2 of 10 on acetaminophen once or twice a day
Appetite and weightFive small meals a day; weight 60.6 kg
Associated signs and symptomsNo jaundice, itching, dark urine, fever, or vomiting
His requestTo see the images and hear the findings and choices plainly

Review of Systems

SystemResultFinding
ConstitutionalPositiveWeight down a further 0.4 kg; tired in the evenings; no fever
GastrointestinalPositiveAche under the right ribs, 2 of 10; early fullness; no vomiting, jaundice, or pale stools
RespiratoryNegativeNo cough or breathlessness
IntegumentaryNegativeNo itching; biopsy site healed

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Acetaminophen 500 mg oral tablet, two tablets by mouth every 8 hours as needed for right upper abdominal ache; no more than 3,000 mg a dayTwo tablets by mouth every 8 hours as needed, no more than 3,000 mg a dayOral route1924-05-04activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1924-05-18Body height165cmS
1924-05-18Body weight60.6kgS
1924-05-18Body mass index (BMI) [Ratio]22.3kg/m2S
1924-05-18Systolic blood pressure128mm[Hg]S
1924-05-18Diastolic blood pressure82mm[Hg]S
1924-05-18Heart rate86/minS
1924-05-18Respiratory rate16/minS
1924-05-18Body temperature36.8CelS
1924-05-18Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1924-05-18ECOG Performance Status score1{score}S

Physical Exam

Vital signs recorded on 1924-05-18; see the Vital Signs section. [S]

SystemFinding
GeneralThin, well; blood pressure 128/82, pulse 86; weight 60.6 kg; no jaundice
AbdomenFirm, non-tender mass felt 4 cm below the right costal margin, moving with breathing; no ascites; no splenomegaly
Lymph nodesNo supraclavicular or umbilical nodes

Problems

ProblemClinical statusVerificationCodeProvenance
Right upper quadrant abdominal mass with weight loss: a dull ache under the right ribs and early fullness for about three months, 4 kg weight loss, and a firm, non-tender mass felt 4 cm below the right costal margin; no jaundice, fever, or itching. Ultrasound today: a 6.8 cm solid, heterogeneous mass in liver segments IV and V that cannot be separated from the gallbladder, which contains stones; the rest of the liver is smooth, with no ascites. Multiphase CT, tumor markers, hepatitis serology and medical oncology consultation arrangedresolvedconfirmed R19.01S — Synthetic presenting problem anchored to the documented right upper abdominal mass; superseded by the biopsy diagnosis.
Adenocarcinoma of the gallbladder invading the liver: core biopsy of the liver mass shows moderately differentiated adenocarcinoma (CK7 positive, CK20 and CDX2 negative), and multiphase CT and MRI show a 7.1 cm mass arising from the gallbladder fundus and invading liver segments IVb and V, with gallstones and two enlarged nodes in the hepatoduodenal ligament; no cirrhosis; alpha-fetoprotein normal, CA 19-9 raised. Clinical T3 N1 before staging laparoscopy (AJCC 8th edition). Synthetic modern episode linked to his documented final illness, described in life as liver cancer and at autopsy as gallbladder adenocarcinomaactiveconfirmed C23S — Synthetic modern diagnosis chosen to fit the documented findings: a mass involving the liver at operation and gallbladder adenocarcinoma at autopsy.
Resolved hepatitis B infection: hepatitis B surface antigen negative, total core antibody positive, surface antibody positive, HBV DNA undetectable; hepatitis C antibody negative. At risk of reactivation during chemotherapy and immunotherapy; monitoredactiveconfirmed Z86.19S — Synthetic serology; not a claim that he had hepatitis B in his lifetime. No fetched source mentions hepatitis.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ImagingMultiphase contrast CT or MRI of the liverAt presentation of a liver massCompleted todayMass arises from the gallbladder and invades segments IVb and V; non-cirrhotic liver; no other liver lesions
ImagingCT of the chest, abdomen and pelvisAt staging, then every 2 to 3 months on treatmentCompleted todayTwo enlarged hepatoduodenal ligament nodes; no distant disease on CT; 6 mm calcified lung granuloma
LaboratoryCore biopsy of the massWhen imaging cannot make the diagnosis (non-cirrhotic liver)Completed todayAdenocarcinoma, CK7 positive, CK20 and CDX2 negative: pancreatobiliary origin
LaboratoryAlpha-fetoproteinAt presentation of a liver massUp to date3.2 ng/mL at intake; normal
LaboratoryCA 19-9 (and CEA when raised)At diagnosis, then with each cycle or restagingUp to dateCA 19-9 412 U/mL and CEA 8.6 ng/mL at intake
LaboratoryLiver function: Child-Pugh and ALBIAt diagnosis, then before each treatment decisionCompleted todayChild-Pugh A6; ALBI grade 2; bilirubin 0.9 mg/dL and INR 1.0 at intake
LaboratoryHepatitis B and C serologyBefore chemotherapy or immunotherapyCompleted todaySurface antigen negative, core antibody positive, surface antibody positive, HBV DNA undetectable; hepatitis C antibody negative
SurveyECOG performance statusEvery visitCompleted todayECOG 1
ExaminationWeight and nutritionEvery visitCompleted today60.6 kg, down 0.4 kg in two weeks; dietitian booked
SurveyPainEvery visitCompleted today2 of 10 on acetaminophen
ReferralMultidisciplinary tumor boardBefore treatment of a biliary tract cancerOrderedIn two days
ImagingStaging laparoscopyBefore resection of gallbladder cancerOrderedIn about ten days, with a port
LaboratoryComprehensive genomic profiling of tumor tissueAt diagnosis of advanced diseaseOrderedSent on the biopsy tissue
ReferralMedical oncologyAt diagnosisCompleted todaySeen by Dr. Choi today
ReferralSpecialist palliative careFrom the diagnosis of advanced cancerDueIntroduced today; first meeting after staging, at his choice

Goal progress:

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Biliary Tract Cancers (2026); AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma (2023); Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update (2020); Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update (2017)

Follow-up: Tumor board in two days; staging laparoscopy in about ten days. Visit in two weeks with the result and the tumor board recommendation. Next scheduled visit 1924-06-01: staging laparoscopy result and tumor board recommendation; first cycle of chemoimmunotherapy and specialist palliative care. [S]